Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Summary

This phase II trial is to see if bevacizumab works in treating patients who have persistent or recurrent cancer of the cervix. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them.

Timeline

Start

2002-04

Primary completion

2009-07

Completion

2009-07

Drugs

Indications